Exenatide (ByettaTM), the first such compound to be licensed by the European Medicine Agency (EMEA) [18], enhances glucose-dependent insulin secretion, regulates glucagon release, and delays gastric emptying thereby reducing hyperglycaemia in a similar manner to GLP-1. Here, GCG is linked to Hyperglycemia.